Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade

Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade

In patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, achievement of pathologic complete response (pCR) is a known prognostic indicator after neoadjuvant systemic therapy (NAST). We investigated the clinicopathological factors associated with pCR in patients with H...

Full description

Bibliographic Details
Main Authors: Soong June Bae, Jee Hung Kim, Min Ji Lee, Seung Ho Baek, Yoonwon Kook, Sung Gwe Ahn, Yoon Jin Cha, Joon Jeong
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
breast neoplasm
neoadjuvant therapy
HER2-targeted therapy
HER2 expression
tumor-infiltrating lymphocyte
Online Access:https://www.mdpi.com/2072-6694/16/4/842

Internet

https://www.mdpi.com/2072-6694/16/4/842

Similar Items